keyword
MENU ▼
Read by QxMD icon Read
search

CKD infections

keyword
https://www.readbyqxmd.com/read/29344021/relevance-of-endothelial-cell-specific-molecule-1-endocan-plasma-levels-for-predicting-pulmonary-infection-after-cardiac-surgery-in-chronic-kidney-disease-patients-the-endolung-pilot-study
#1
Andréa Perrotti, Camille Chenevier-Gobeaux, Fiona Ecarnot, Benoit Barrucand, Philippe Lassalle, Enrica Dorigo, Sidney Chocron
Objectives: This pilot study aimed to evaluate the relevance of endocan plasma levels for predicting pulmonary infection after cardiac surgery in patients with chronic kidney disease (CKD). Methods: Serum collected in a previous prospective cohort study (from 166 patients with preoperative CKD who underwent cardiac surgery) was used. Five patients with postoperative pulmonary infection were compared with 15 randomly selected CKD patients with an uneventful outcome...
December 2017: Cardiorenal Medicine
https://www.readbyqxmd.com/read/29337400/immunization-in-end-stage-renal-disease-the-perception-of-waiting-list-patients
#2
L F Camargo, A M Lother, M Mazzali, R S B Stucchi
BACKGROUND: The number of patients with chronic kidney disease is increasing worldwide, as well as the number of patients in kidney transplant waiting lists. In order to prevent infections related to immunosuppressive therapy, immunization guidelines for CKD patients before transplantation have been proposed. The aim of the present study was to evaluate adherence to immunization in a cohort of CKD patients in transplant waiting list and their renal replacement therapy clinics. METHODS: CKD patients older than 18 years old, receiving renal replacement therapy longer than12 months and included in kidney transplant waiting list at University of Campinas (Unicamp) were enrolled...
January 16, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29327401/daclatasvir-and-reduced-dose-sofosbuvir-an-effective-and-pangenotypic-treatment-for-hepatitis-c-in-patients-with-egfr-30-ml-min
#3
Amit Goel, Dharmendra Singh Bhadauria, Anupma Kaul, Prashant Verma, Mayank Mehrotra, Amit Gupta, Raj Kumar Sharma, Praveer Rai, Rakesh Aggarwal
BACKGROUND & AIMS: Sofosbuvir is a key agent for HCV treatment. It is not recommended for patients with chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR) <30 mL/min. We report real-life experience of treating a cohort of CKD patients with eGFR <30 mL/min using daclatasvir and half-daily dose of sofosbuvir. METHODS: Adults patients who (i) had eGFR<30 ml/min and detectable HCV RNA and (ii) were treated with interferon and ribavirin free, DAA based regimens were included...
January 12, 2018: Nephrology
https://www.readbyqxmd.com/read/29317911/a-quality-assurance-investigation-of-clabsi-events-are-there-exceptions-to-never
#4
Samantha Strickler, Rohit R Gupta, John T Doucette, Roopa Kohli-Seth
Background: In the USA, central line associated blood stream infections (CLABSIs) have been designated as 'never events', prompting initiatives towards a 'zero CLABSIs' standard. We propose that there are cascading risk factors predisposing certain patient cohorts to higher CLABSIs rates. Methods: A retrospective review of all CLABSI infections over a 12-month period was undertaken. Risk factors examined included catheter type, insertion site and parenteral nutrition (PN) status...
January 2018: Journal of Infection Prevention
https://www.readbyqxmd.com/read/29316051/safety-and-efficacy-of-sofosbuvir-and-ribavirin-for-genotype-2-hepatitis-c-japanese-patients-with-renal-dysfunction
#5
Takuya Sho, Goki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, Ken Furuya, Kenichi Kumagai, Minoru Uebayashi, Katsumi Terashita, Tomoe Kobayashi, Izumi Tsunematsu, Manabu Onodera, Takashi Meguro, Megumi Kimura, Jun Ito, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masatsugu Ohara, Yuji Ono, Masato Nakai, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto
BACKGROUND AND AIM: The safety and efficacy of sofosbuvir and ribavirin have not been well clarified in patients with renal dysfunction because clinical trials did not include such patients. We evaluated the safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C virus (HCV)-infected patients with renal dysfunction. METHODS: The study included genotype 2 HCV-infected patients who received sofosbuvir and ribavirin between July 2014 and May 2017...
January 9, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29301137/associations-of-fibroblast-growth-factor-23-with-markers-of-inflammation-and-leukocyte-transmigration-in-chronic-kidney-disease
#6
Carin Wallquist, Ladan Mansouri, Mattias Norrbäck, Britta Hylander, Stefan H Jacobson, Tobias E Larsson, Joachim Lundahl
BACKGROUND: Patients with chronic kidney disease (CKD) show elevated levels of inflammatory markers and have an increased risk of infections as well as cardiovascular morbidity. Recent studies have implied effects of fibroblast growth factor 23 (FGF23) on inflammation in CKD. We analyzed potential correlations between levels of FGF23 with pro-inflammatory chemokines and markers of leukocyte transmigration in CKD patients. METHODS: One hundred three patients with CKD 2-5ND and 54 healthy controls, had biochemical markers in blood and urine analyzed according to routine protocol...
January 4, 2018: Nephron
https://www.readbyqxmd.com/read/29295829/medication-therapy-management-after-hospitalization-in-ckd-a-randomized-clinical-trial
#7
Katherine R Tuttle, Radica Z Alicic, Robert A Short, Joshua J Neumiller, Brian J Gates, Kenn B Daratha, Celestina Barbosa-Leiker, Sterling M McPherson, Naomi S Chaytor, Brad P Dieter, Stephen M Setter, Cynthia F Corbett
BACKGROUND AND OBJECTIVES: CKD is characterized by remarkably high hospitalization and readmission rates. Our study aim was to test a medication therapy management intervention to reduce subsequent acute care utilization. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The CKD Medication Intervention Trial was a single-blind (investigators), randomized clinical trial conducted at Providence Health Care in Spokane, Washington. Patients with CKD stages 3-5 not treated by dialysis who were hospitalized for acute illness were recruited...
January 2, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/29288514/high-efficacy-of-ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-in-hepatitis-c-genotypes-4-and-1-infected-patients-with-severe-chronic-kidney-disease
#8
Faisal M Sanai, Abdullah S Alghamdi, Ahmad A Afghani, Khalid Alswat, Adnan AlZanbagi, Mosfer N Alghamdi, Abdallah AlMousa, Mohammed Aseeri, Abdullah M Assiri, Mohamed A Babatin
Limited data has shown high efficacy of co-formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in the treatment of hepatitis C virus (HCV) genotype (GT)-4, and combined with dasabuvir (DSV) in GT1 patients, with chronic kidney disease (CKD) stage 4-5 (<30 mL/min/1.73 m2 ). We assessed real-world safety and efficacy of OBV/PTV/r ± DSV in GT1 and 4-infected patients. METHODS: In this observational cohort (n=67), we enrolled stage 4-5 CKD treatment-naïve or Peginterferon/RBV-experienced GT4-infected patients (n=32) treated for 12-24 weeks with OBV/PTV/r ± RBV, and plus DSV in GT1 patients (n=35, including 3 with GT1/4 co-infection)...
December 29, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29282226/maternal-and-fetal-outcomes-of-pregnancies-in-women-with-atypical-hemolytic-uremic-syndrome
#9
Martina Gaggl, Christof Aigner, Dorottya Csuka, Ágnes Szilágyi, Zoltán Prohászka, Renate Kain, Natalja Haninger, Maarten Knechtelsdorfer, Raute Sunder-Plassmann, Gere Sunder-Plassmann, Alice Schmidt
Atypical HUS (aHUS) is a disorder most commonly caused by inherited defects of the alternative pathway of complement, or the proteins that regulate this pathway, and life-threatening episodes of aHUS can be provoked by pregnancy. We retrospectively and prospectively investigated 27 maternal and fetal pregnancy outcomes in 14 women with aHUS from the Vienna Thrombotic Microangiopathy Cohort. Seven pregnancies (26%) were complicated by pregnancy-associated aHUS (p-aHUS), of which three appeared to be provoked by infection, bleeding, and curettage, and three individuals were considered to have preeclampsia/HELLP syndrome before the definitive diagnosis of p-aHUS was made...
December 27, 2017: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/29250687/lymphoproliferative-disorder-in-a-twin-female-teenager-post-kidney-transplantation
#10
Raluca Isac, Rodica Costa, Dorela CodruŢa Lăzureanu, Cristina Ioana Olariu, Adriana Milena Muntean, Cornel Olimpiu Aldea, Gabriela Simona Doroş, Mihai Gafencu
Post-transplant lymphoproliferative disorder (PTLD) is defined as a heterogeneous group of lymphoid and plasmocytic proliferations with variable malignant potential. They often arise in immunocompromised post solid organ transplant (SOT) patients linked with Epstein-Barr virus (EBV) infection. Clinical manifestations include fever, lymphadenopathy and organ involvement. Diagnosis of PTLD requires morphopathological tissue examination. Treatment of EBV-related PTLD in SOT patients includes immunosuppressive (IS) agents' reduction, use of antiviral medication, anti-B-lymphocyte antibodies and chemotherapy for high-risk patients...
2017: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/29245978/chronic-kidney-disease-is-associated-with-a-risk-of-higher-mortality-following-total-knee-arthroplasty-in-diabetic-patients-a-nationwide-population-based-study
#11
Liang-Tseng Kuo, Su-Ju Lin, Chi-Lung Chen, Pei-An Yu, Wei-Hsiu Hsu, Tien-Hsing Chen
Diabetes and chronic kidney disease (CKD) are associated with a higher rate of complications in patients undergoing total knee arthroplasty (TKA). The purpose of this study was to determine the effects of CKD and diabetes in patients after TKA. Diabetic patients who received unilateral primary TKA between January 2008 and December 2011 were enrolled. The follow-up period was more than 6 months. The primary outcome was a TKA-related infection and the secondary outcome was all-cause mortality. The study cohort included 13844 patients who were followed for a mean period of 2 years, of whom 1459 (10...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29233630/higher-risk-of-renal-disease-in-chronic-hepatitis-c-patients-antiviral-therapy-survival-benefit-in-patients-on-hemodialysis
#12
Jonas Söderholm, Charlotta Millbourn, Katharina Büsch, Jan Kövamees, Robert Schvarcz, Karin Lindahl, Annette Bruchfeld
BACKGROUND & AIMS: Several studies have shown that chronic hepatitis C (CHC) infection has a negative impact on kidney function, as well as survival, in patients with chronic kidney disease (CKD) or on hemodialysis (HD). The aim of this nationwide registry study was to describe renal disease in Swedish CHC patients METHODS: In the present study, patients were identified for CHC (B18.2) and CKD (N18) according to the International Classification of Diseases (ICD)-10 in the nationwide Swedish inpatient care day surgery (1997-2013) and non-primary outpatient care (2001-2013) patient registries...
December 9, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29229166/holding-water-congenital-anomalies-of-the-kidney-and-urinary-tract-ckd-and-the-ongoing-role-of-excellence-in-plumbing
#13
REVIEW
Lars J Cisek
Congenital anomalies of the kidneys and urinary tracts can result in diminished natal kidney function, possibly through common embryologic pathway disruption or as a result of development taking place in the face of disordered 'post-renal' drainage. Impaired conduit and reservoir function present potential for an ongoing assault leading to further deterioration and progression of chronic kidney disease, a risk that extends to adults with these conditions, even after "correction". The drainage and storage aspects of the urinary system that can impact kidney function are reviewed with attention to correctable or manageable problems including: Bladder dysfunction wherein the low pressure storage of urine is compromised requiring the kidney to work against a pressure gradient, the classic post renal failure problem...
November 2017: Advances in Chronic Kidney Disease
https://www.readbyqxmd.com/read/29212486/emerging-concepts-and-spectrum-of-renal-injury-following-intravesical-bcg-for-non-muscle-invasive-bladder-cancer
#14
Azharuddin Mohammed, Zubair Arastu
BACKGROUND: Intravesical Bacilli Calmette-Guerin (IVBCG) therapy for non-muscle invasive bladder cancer (NMIBC) has long been in use successfully. Albeit rarely, we still face with its safety concerns more than 25 years on since its approval by US Food and Drug Agency in 1990. Local and systemic infection following intravesical BCG is widely reported as compared to immune mediated local or systemic hypersensitivity reactions involving kidneys; acute kidney injury (AKI) and other renal manifestations are well reported but not of chronic kidney disease (CKD)...
December 6, 2017: BMC Urology
https://www.readbyqxmd.com/read/29210830/tenofovir-associated-nephrotoxicity-among-a-us-national-historical-cohort-of-hiv-infected-veterans-risk-modification-by-concomitant-antiretrovirals
#15
Joanne LaFleur, Adam P Bress, Stephen Esker, Kristin Knippenberg, Jacob Crook, Heather Nyman, Roger Bedimo, Pablo Tebas, Lisa Rosenblatt
BACKGROUND: Tenofovir disoproxil fumarate (TDF) has been associated with renal complications. The third agent in TDF-containing antiretroviral regimens may modify that risk. We compared renal adverse outcomes among treatment-naïve HIV-infected patients initiating TDF-containing regimens including efavirenz (EFV) or other agents. SETTING: This population-based historical cohort study used national Veterans Health Administration (VHA) clinical and administrative datasets to identify treatment-naïve HIV-infected veterans initiating antiretroviral therapy (ART) with TDF/emtricitabine (FTC)+EFV, rilpivirine (RPV), elvitegravir/cobicistat (EVG/c), or ritonavir (RTV)-boosted protease inhibitors (PIs) from 2003-2015...
November 27, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29187303/prevalence-and-characteristics-of-chronic-kidney-disease-among-danish-adults-with-cystic-fibrosis
#16
Kristina H Berg, Lene Ryom, Daniel Faurholt-Jepsen, Tania Pressler, Terese L Katzenstein
BACKGROUND: With improved prognosis of CF, comorbidities including chronic kidney disease (CKD) are becoming increasingly important. Identification of those at highest CKD risk is hence a priority. METHODS: In this cross-sectional study, adults with CF attending the Copenhagen CF Centre at Rigshospitalet with ≥2 measurements of serum creatinine from 2013 to 2015 were included. Data was obtained from an electronic CF database, which contains anonymised clinical and laboratory data on all individuals attending the clinic...
November 27, 2017: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://www.readbyqxmd.com/read/29175613/chronic-kidney-disease-after-acute-kidney-injury-associated-with-intravenous-colistin-use-in-survivors-of-severe-infections-a-comparative-cohort-study
#17
Alejandro Meraz-Muñoz, Ismael Gomez-Ruiz, Ricardo Correa-Rotter, Juan C Ramirez-Sandoval
PURPOSE: The use of colistin for multi-drug resistant (MDR) infections has led to an increase of colistin-associated acute kidney injury (AKI). Nevertheless, information on long-term renal prognosis is scarce. We aimed to determine the predictors of chronic kidney disease (CKD) in survivors of MDR-infections with colistin-associated AKI. METHODS: A retrospective cohort of patients with colistin-associated AKI was compared with controls (survivors of severe infections who developed AKI matched by age, sex, diabetes, vancomycin exposure, and baseline kidney function)...
November 15, 2017: Journal of Critical Care
https://www.readbyqxmd.com/read/29159457/ertugliflozin-in-patients-with-stage-3-chronic-kidney-disease-and-type-2-diabetes-mellitus-the-vertis-renal-randomized-study
#18
George Grunberger, Sarah Camp, Jeremy Johnson, Susan Huyck, Steven G Terra, James P Mancuso, Zhi Wei Jiang, Gregory Golm, Samuel S Engel, Brett Lauring
INTRODUCTION: Ertugliflozin is a sodium-glucose cotransporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The safety and efficacy of ertugliflozin were evaluated over 52 weeks in patients with chronic kidney disease (CKD). METHODS: In this double-blind randomized study (NCT01986855), patients with glycated hemoglobin (A1C) 7.0-10.5% and stage 3 CKD [estimated glomerular filtration rate (eGFR) ≥ 30 to < 60 mL/min/1.73 m(2)] who were undergoing treatment with standard diabetes therapy (or therapies) including insulin and/or sulfonylureas were randomized to once-daily ertugliflozin 5 mg, 15 mg, or placebo...
November 20, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29135575/chronic-kidney-disease-incidence-and-survival-of-thai-hiv-infected-patients
#19
Wannarat Pongpirul, Krit Pongpirul, Jintanat Ananworanich, Virat Klinbuayaem, Anchalee Avihingsanon, Wisit Prasithsirikul
OBJECTIVES: As data on chronic kidney disease (CKD) incidence among Asian HIV patients has been limited, the present study aimed to estimate the CKD incidence in HIV-infected patients who received standard antiretroviral therapy in Thailand and to compare baseline demographics and clinical characteristics of the patients who developed CKD with those who do not. DESIGN: A multicenter, observational prospective cohort of HIV patients with normal kidney functions who received standard antiretroviral therapy...
January 28, 2018: AIDS
https://www.readbyqxmd.com/read/29130991/pre-end-stage-renal-disease-hemoglobin-variability-predicts-post-end-stage-renal-disease-mortality-in-patients-transitioning-to-dialysis
#20
Keiichi Sumida, Charles Dyer Diskin, Miklos Z Molnar, Praveen K Potukuchi, Fridtjof Thomas, Jun Ling Lu, Connie M Rhee, Elani Streja, Kunihiro Yamagata, Kamyar Kalantar-Zadeh, Csaba P Kovesdy
BACKGROUND: Hemoglobin variability (Hb-var) has been associated with increased mortality both in non-dialysis dependent chronic kidney disease (NDD-CKD) and end-stage renal disease (ESRD) patients. However, the impact of Hb-var in advanced NDD-CKD on outcomes after dialysis initiation remains unknown. METHODS: Among 11,872 US veterans with advanced NDD-CKD transitioning to dialysis between October 2007 through September 2011, we assessed Hb-var calculated from the residual SD of at least 3 Hb values during the last 6 months before dialysis initiation (prelude period) using within-subject linear regression models, and stratified into quartiles...
2017: American Journal of Nephrology
keyword
keyword
55523
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"